Wall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to Hold

TransMedics Group (NASDAQ:TMDX) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research analysts have also commented on the stock. Needham & Company LLC raised their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Evercore ISI initiated coverage on shares of TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price target for the company. Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Canaccord Genuity Group increased their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Trading Up 5.5%

Shares of NASDAQ TMDX opened at $127.67 on Friday. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The stock has a market capitalization of $4.36 billion, a PE ratio of 51.69 and a beta of 2.06. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $156.00. The stock has a fifty day simple moving average of $127.74 and a 200-day simple moving average of $122.91.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.TransMedics Group’s revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 EPS. On average, equities analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insider Activity

In other news, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the transaction, the director owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. The trade was a 59.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 13,062 shares of company stock worth $1,797,634. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently bought and sold shares of TMDX. Nuveen LLC acquired a new position in shares of TransMedics Group during the 1st quarter worth about $5,927,000. HighTower Advisors LLC lifted its stake in TransMedics Group by 137.7% during the first quarter. HighTower Advisors LLC now owns 18,257 shares of the company’s stock worth $1,228,000 after purchasing an additional 10,575 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in TransMedics Group by 135.8% in the first quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock valued at $9,782,000 after purchasing an additional 83,722 shares in the last quarter. Algert Global LLC increased its stake in TransMedics Group by 8.9% in the first quarter. Algert Global LLC now owns 13,674 shares of the company’s stock valued at $920,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Northern Trust Corp increased its stake in TransMedics Group by 2.1% in the first quarter. Northern Trust Corp now owns 361,963 shares of the company’s stock valued at $24,353,000 after purchasing an additional 7,341 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.